Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Adaptimmune Therapeutics Plc ADR shares valued at $22,814 were sold by Piccina Cintia on Jun 18 ’24. At $0.93 per share, Piccina Cintia sold 24,531 shares. The insider’s holdings dropped to 38,293 shares worth approximately $23358.73 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Rawcliffe Adrian sold 30,080 shares, netting a total of over 20,244 in proceeds. Following the sale of shares at $0.67 each, the insider now holds 44,848 shares.
Before that, Rawcliffe Adrian had sold 9,304 shares from its account. In a trade valued at $7,350, the Chief Executive Officer traded Adaptimmune Therapeutics Plc ADR shares for $0.79 each. Upon closing the transaction, the insider’s holdings decreased to 9,304 shares, worth approximately $8603.44.
As published in their initiating research note from H.C. Wainwright on July 30, 2024, Adaptimmune Therapeutics Plc ADR [ADAP] has been a Buy and the price target has been revised to $4. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in late May. As of March 24, 2023, Bryan Garnier has initiated its “Buy” rating for ADAP. Earlier on January 03, 2023, Guggenheim upgraded its rating. Their new recommendation was “a Buy” for ADAP stock which previously was a “a Neutral”.
Analyzing ADAP Stock Performance
During the last five days, there has been a drop of approximately -4.57%. Over the course of the year, Adaptimmune Therapeutics Plc ADR shares have dropped approximately -23.58%. Shares of the company reached a 52-week high of $2.0500 on 03/08/24 and a 52-week low of $0.5511 on 12/13/24. A 50-day SMA is recorded $0.7310, while a 200-day SMA reached $1.0482. Nevertheless, trading volume fell to 3.27 million shares from 2.62 million shares the previous day.
Support And Resistance Levels for Adaptimmune Therapeutics Plc ADR (ADAP)
According to the 24-hour chart, there is a support level at 0.5864, which, if violated, would cause prices to drop to 0.5667. In the upper region, resistance lies at 0.6293. The next price resistance is at 0.6525. RSI (Relative Strength Index) is 37.97 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0487, which suggests the price will decrease in the coming days. Percent R is at 70.94%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
